PGx, the study of how genes affect a person’s response to drugs, combines the fields of pharmacology and genomics to develop effective, safe medications and dosing recommendations tailored to a person’s genetic makeup. PGx testing may help reduce adverse drug reactions (ADRs), which some estimates place as the fourth leading cause of death – resulting in more deaths than lung disease, diabetes, AIDS, pneumonia, and accidents. For every healthcare dollar spent on medications, an additional 50% is spent on addressing ADRs. Admera Health’s flagship product, PGxOne™ Plus, is a comprehensive test built on the foundation of enabling smarter and safer medication management. The test incorporates next-generation gene sequencing design applications and expert data curation to deliver biological systems based medically actionable results. In addition to PGx services, Admera Health leverages existing knowledge and infrastructure to offer related clinical services and robust biopharmaceutical genomics solutions to researchers worldwide.
Location: United States, New Jersey, South Plainfield
Employees: 51-200
Phone: +1 908-222-0533
Founded date: 2014
Mentions in press and media 13
| Date | Title | Description |
| 23.10.2024 | Admera Health Expands its Reach with Strategic Acquisition of German-based BioEcho | The EchoLUTION Kit by BioEcho – a cutting-edge DNA/RNA extraction solution, now part of Admera Health’s expanded genomics toolkit, enabling faster and purer sample processing. Admera Health acquires Germany's BioEcho, boosting its NGS servi... |
| 12.06.2024 | Singleron Biotechnologies Appoints Admera Health as their Certified US Service Provider | Welcome to the Advanced Molecular Era BOSTON, MASSACHUSETTS, UNITED STATES, June 12, 2024 /EINPresswire.com/ -- Singleron Biotechnologies and Admera Health announced their strategic alliance at this year’s Festival of Genomics & Biodata... |
| 04.04.2024 | STOmics to Welcome Admera Health into its Certified Service Provider Program | STOmics to Welcome Admera Health into its Certified Service Provider program for Stereo-seq, its Spatial Transcriptomics platform. SAN DIEGO, CALIFORNIA, USA, April 4, 2024 /EINPresswire.com/ -- Admera Health, a leading provider of Next-Gen... |
| 29.03.2023 | Admera Health Announces its Acquisition of a NovaSeq X Plus | Welcome to the Advanced Molecular Era The NovaSeq X Plus is a game-changer in the world of sequencing, and we are excited to leverage its capabilities to advance sequencing-based research” — Yun Zhao, CEO SOUTH PLAINFIELD, NEW JERSEY, USA, ... |
| 17.08.2020 | Health tech companies claim their largest share of the Inc. 5,000 to date with 123 entries | |
| 23.08.2019 | 61 health tech companies report 2018 revenues, feature on Inc. 5,000 list | |
| 28.02.2017 | Mayo Clinic startup OneOme pitches user-friendly pharmacogenomics | The OneOme pharmacogenomic test kit Investigational drugs in the U.S. are required to undergo ‘ADME‘ pharmacology testing to characterize Absorption, Distribution, Metabolism and Excretion. The problem is that individuals process drugs diff... |
| 12.01.2016 | GENEWIZ receives investment from OrbiMed for growth in its DNA sequencing, gene synthesis | A GENEWIZ representative was not available to comment on how much was raised or how the round of financing will be used. OrbiMed recently announced the closing of a major fund, bringing in $950 million with the help of investments from medi... |
| 11.11.2015 | Other diagnostic companies utilize regulatory loopholes, not just Theranos | One benefit of the LDT loophole is the opportunity to keep methods secret – there’s no reason companies would need to publish data. “Their intellectual property is know-how and that’s something that they want to keep as trade secrets,” Mich... |
| 07.04.2015 | Admera Health Completes Series A Financing | Admera Health, a South Plainfield, NJ-based molecular diagnostics company focused on personalized medicine, completed a Series A round of financing of undisclosed amount. The round was led by Prime Value Capital Management (PVCM) with parti... |
Show more